MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1177/13872877261489619

Медицинская библиотека · Journal of Alzheimer's disease : JAD · 2026

Clinical utility of combined amyloid biomarkers in early cognitive impairment.

Chiang Pu-Tien, Cheng Shao-Ying, Hsueh Sung-Ju, Lin Sheng-Sian, Lee Bo-Ching, Liu Chia-Ju, Lin Yu-Hung, Huang Shang-Chin, Tsai Li-Kai, Tsai Hsin-Hsi

СтатьяПеревод в очереди

Аннотация

BackgroundEarly etiological diagnosis of cognitive impairment is challenging. Amyloid PET improves diagnostic accuracy but is costly and limited in availability. Plasma phosphorylated tau-217 (p-tau217) has emerged as a scalable, minimally invasive biomarker.ObjectiveThis study aimed to evaluate the diagnostic and prognostic utility of amyloid PET and plasma p-tau217 in older adults with early cognitive impairment.MethodsWe prospectively enrolled 100 adults aged ≥ 65 years with mild cognitive impairment or mild dementia. Participants underwent comprehensive clinical evaluation, brain MRI, 18F-florbetaben amyloid PET, and plasma p-tau217 analysis. Longitudinal cognitive decline was assessed over a median follow-up of 1.3 years.ResultsAmyloid PET was positive in 45% and resulted in diagnostic revision in 39%. Plasma p-tau217 levels were significantly higher in amyloid-positive individuals (1.178 ± 0.652 versus 0.642 ± 0.940 pg/mL, p < 0.001) and accurately identified amyloid positivity (AUC = 0.855). Both amyloid PET positivity (HR = 6.61, 95% CI 2.36-18.50; p < 0.001) and elevated p-tau217 (HR = 4.43, 95% CI 1.83-10.68; p = 0.001) independently predicted faster cognitive decline. Combined biomarker analysis revealed a stepwise risk stratification, with dual-positive individuals showing the most rapid deterioration (global p < 0.001). Among amyloid-positive patients, elevated p-tau217 further distinguished those with faster progression (p = 0.035).ConclusionsAmyloid PET and plasma p-tau217 provide complementary diagnostic and prognostic value. While PET refines etiological diagnosis, p-tau217 serves as a robust predictor of amyloid status and cognitive trajectory. Integrating these biomarkers improves risk stratification and may facilitate patient selection for disease-modifying therapies.

Для цитирования: Chiang Pu-Tien, Cheng Shao-Ying, Hsueh Sung-Ju, Lin Sheng-Sian, Lee Bo-Ching, Liu Chia-Ju, Lin Yu-Hung, Huang Shang-Chin, Tsai Li-Kai, Tsai Hsin-Hsi. Clinical utility of combined amyloid biomarkers in early cognitive impairment.. Journal of Alzheimer's disease : JAD. 2026. DOI: 10.1177/13872877261489619.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.